| 3244 | Vojtech Huser | National Library of Medicine/NIH | Identification of Research Common Data Elements in HIV/AIDS using data science methods | AbbVie, Pfizer |
| 3246 | Dawn Farrell | Institute of Technology Tralee | Cochrane Review: Interventions for fatigue in inflammatory bowel disease | AbbVie |
| 3270 | Mirjana Stanic Benic | University Hospital Centre Rijeka | The impact of biological interventions on health‐related quality of life in adults with Crohn's disease | AbbVie, Biogen |
| 3287 | Robert Alexander | Takeda | Identification of biomarkers associated with specific sleep variables | GSK |
| 3288 | Marc-Antoine Sparfel | Tours Hospital | MIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trials | AbbVie, Pfizer, UCB |
| 3320 | John Frew | Rockefeller University | Analysis of Outcome Measures in Hidradenitis Suppurativa | AbbVie |
| 3321 | Ewa Olech | IQVIA | Study of entry variables to optimize lupus trial design | GSK |
| 3328 | Klaus Gottlieb | Eli Lilly USA | Mapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s disease | Takeda |
| 3361 | Gustav Nilsonne | Karolinska Institutet | Distribution of interleukin -6 in human plasma implications for statistical modelling and meta-analysis | AbbVie, GSK |
| 3369 | Michael Ward
| NIH | Predicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing Spondylitis | AbbVie, Pfizer |
| 3762 | Lin Wang | Johns Hopkins Hospital | The relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
| Pfizer, Project Data Sphere |
| 3876 | Changyu Shen | Beth Israel Deaconess Medical Center | Risk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation | Boehringer Ingelheim, Daiichi Sankyo |
| 4036 | Akira Kimata | University of Tsukuba | Optimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trials | Boehringer Ingelheim
|
| 4037 | Karl Peace | Georgia Southern University | Assessment of Matching Methods for Causal Analysis
| Boehringer Ingelheim
|
| 4039 | Claire Daien | CHU lapeyronie | The most appropriate conventional DMARD to combine with tofacitinib in Rheumatoid Arthritis post hoc analysis of ORAL sync study | Pfizer |
| 4041 | Vivek Rudrapatna | University of California, San Francisco | Enhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative Colitis | AbbVie, Johnson & Johnson, Takeda |
| 4043 | Janneke van der Woude | Erasmus Medical Center | Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis | Pfizer |
| 4047 | Miriam Oron
| Skintelligence ltd. | Test the prospects of expending the Skintelligence algorithm for predicting response to treatment with Alefacept and Ustekinumab in psoriatic patients affected with type I diabetes | ImmPort |
| 4112 | Florian Naudet | CHU Rennes | Tolerability of duloxetine in the elderly and in adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placebo | AbbVie, Lilly, Lundbeck, Pfizer, Takeda |
| 4113 | Lesley Inker | Tufts Medical Center | Chronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT) | GSK, Takeda |
| 4115 | Amir Mahabadi | University Hospital Essen, West German Heart and Vascular Center | Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trials | Pfizer |
| 4116 | Sharon Strauss | St. Michael’s Hospital | Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysis | AbbVie |
| 4117 | John Frew | Rockefeller University | Predictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis Suppurativa | AbbVie |
| 4118 | J. David Spence | Western University | On-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
| Pfizer |
| 4120 | Merryn Voysey | University of Oxford | The immunogenicity and sero-efficacy of pneumococcal vaccines | Pfizer |
| 4121 | Frederikus Klok | Leiden University Medical Center | Performance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation a post-hoc analysis of the ENGAGE-AF TIMI-48 Study | Daiichi Sankyo |
| 4275 | Lisa Stamp | University of Otago | Serum urate as a biomarker in gout Protocol for individual patient data analysis for OMERACT 2020
| Takeda |
| 4278 | Jennifer Quint | Imperial College London | Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD a real world study
| Boehringer Ingelheim |
| 4316 | Martin Okun | Fort HealthCare | Geospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis | AbbVie |
| 4319 | Maria Alice Franzoi | Jules Bordet Institut | Clinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials. | Lilly |
| 4324 | Peng Xie | Chongqing Medical University | Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analys | GSK, Lilly, Pfizer |
| 4326 | John Markman | University of Rochester | Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical Injury | Pfizer |
| 4327 | Michael Szarek | SUNY Downstate Medical Center | Analysis of Total Events and Hospitalizations in the SPARCL Study | Pfizer |
| 4329, 4048 | Shomron Ben-Horin | Sun Yatsen 1st affiliated Hospital | Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB |
| 4330 | Laure Gossec | Sorbonne Université | Domains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i) | Pfizer |
| 4352 | Stefano Barco | University Medical Center Mainz | Differential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trials | Daiichi Sankyo |
| 4540 | Chris Gale | University of Leeds | Efficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trial | Daiichi Sankyo |
| 4541 | C Elizabeth Caldon | Garvan Institute of Medical Research | Therapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancer | Pfizer |
| 4913 | Susan Halabi | Duke University | Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma | Pfizer, Project Data Sphere |
| 4915 | Rachel Tomko | Medical University of South Carolina | Predicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy | Pfizer |
| 4917 | Andrea Cipriani | University of Oxford | Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-Analysis | GSK, Lilly, Lundbeck |
| 4918 | Nina Hilkens | Radboudmc Nijmegen | Association between blood pressure, blood pressure variability and the risk of post-stroke dementia | Boehringer Ingelheim |
| 4919 | Hendrik Jan Guchelaar | Leiden University Medical Center (LUMC) | Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors | Pfizer |
| 4920 | Gustavo Turecki | Douglas Mental Health University Institute | Predicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters
| Pfizer |
| 4921 | Tim Brümmendorf | University Hospital Aachen | Entropy based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML | Pfizer |
| 4922, 3274 | Diane van der Woude | Leiden University Medical Center | Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | AbbVie, Pfizer |
| 4926 | Eva-Maria Gamper | Medical University Innsbruck | Comparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its use | Boehringer Ingelheim |
| 4931 | Siddharth Singh | University of California, San Diego | Early changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trials | AbbVie, Takeda |
| 4933 | Hongxia Wang | Shanghai Jiao Tong University School of Medicine | Novel predictive biomarker for therapeutic sensitivity of CKD4/6 inhibitor in breast cancer patients | Pfizer |
| 4949, 3190 | Vivek Rudrapatna | University of California San Francisco | Efficacy of Crohn’s Disease Treatment Stratified by Disease Phenotype | AbbVie, Biogen, Johnson & Johnson, Takeda, UCB |
| 4950 | John “Devin” Peipert | Northwestern University | Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development ToolQualification in Rheumatoid Arthritis | AbbVie |
| 5073 | Philip Robinson | University of Queensland | Assessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial data | Pfizer |
| 5074 | Sebastian Zundler | University Hospital Erlangen | Evaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysis | Takeda |
| 5079 | Maureen Dubreuil | Boston University | Clinical and MRI predictors of Clinical Response in Axial Spondyloarthritis | AbbVie |
| 5080 | Joel Skaistis | Beaumont Health | Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker Level | Boehringer Ingelheim |
| 5086 | Junko Takeshita | University of Pennsylvania | A Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic Diseases | AbbVie, Lilly, Regeneron |
| 5095 | Mathilde Nijkeuter | University Medical Center Utrecht | Assessing bleeding risk in patients with cancer-associated thrombosis | Daiichi Sankyo |
| 5096 | Joo Sang Lee | Samsung Medical Center, South Korea | Harnessing genetic interactions to advance precision cancer medicine | Tempus Labs, Inc. |
| 5098 | Christopher Baethge | University of Cologne Medical School | Dose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysis | Lilly |
| 5099 | Jorge Hernando | Vall d ́Hebron University Hospital | Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs) | Pfizer |
| 5163 | Susan Bates | Columbia University Medical Center | Assessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial data | Celgene Corporation |
| 5165 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat
| Takeda |
| 5166 | Thomas Metkus | Johns Hopkins University School of Medicine | Severe sepsis in the cardiac intensive care unit: management strategies and outcomes | Lilly |
| 5207 | Fasihul Khan | University of Nottingham | A systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosis | BioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche |
| 5209 | Bruce Perkins | University of Toronto | TRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOL | Boehringer Ingelheim |
| 5276 | Yan Luo | Kyoto University | Predicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | UCB |
| 5290 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of gastrointestinal cancers | Boehringer Ingelheim, GSK, Lilly, Roche |
| 5291 | Sarah Nevitt | University of Liverpool | Antiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysis | UCB |
| 5292 | Désirée van der Heijde | Leiden University Medical Center | Measurement properties of the instruments used in the outcome assessment of axial spondyloarthritis | UCB |
| 5294 | Daniel Caldeira | University of Lisbon/CCUL | The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY | Boehringer Ingelheim |
| 5325, 5324 | Daniel Goldenholz | Beth Israel Deaconess Medical Center | Retrospective analysis of placebo arm data in clinical epilepsy trials | GSK, UCB |
| 5330 | Laura Bonnett | University of Liverpool | Modelling seizure rates rather than time to an event within clinical trials of antiepileptic drugs | UCB |
| 5352 | Elena Myasoedova | Mayo Clinic | Individualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach
| Roche, UCB |
| 5435 | Matthew Gilbert | University of Vermont | Effect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled Trial | GSK |
| 5436 | Adrian Wagg | University of Alberta | A pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of age | Pfizer |
| 5456 | Ramona Belfiore-Oshan | Critical Path Institute | Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy | CureDuchenne |
| 5483 | David McAllister | University of Glasgow | Assessing heterogeneity in relative treatment efficacy by age, sex and comorbidity. | Boehringer Ingelheim, Lilly, Roche, Takeda, UCB |
| 5567 | Neeraj Narula | McMaster University | Impact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohns Disease: An EXTEND Post-Hoc Analysis | AbbVie |
| 5812 | Yougen Wu | The Fifth People's Hospital of Shanghai, Fudan University | Development and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitors | Roche |
| 5813 | Phillip Garfin | Seattle Genetics Inc. | Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypes | Roche |
| 5852 | Marliese Alexander | Peter MacCallum Cancer Centre | Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysis | Roche |
| 5853 | Florian Naudet | CHU Rennes | Data-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment Reports | AbbVie |
| 5869 | Alexandra Freeman | University of Cambridge | Meta-analysis of the adverse effects of trastuzumab in women with breast cancer | Roche |
| 5871 | Nobuhisa Kanahara | Chiba University Center for Forensic Mental Health | Determination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects | Lilly |
| 5872 | Yaw Nyame | University of Washington Medical Center | Representation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer Trials | Pfizer |
| 5880 | Benjamin Schneider | Iowa State University | Optimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung Cancer | Lilly, Roche |
| 5894 | Takashi Sozu | Tokyo University of Science | Matrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety Profile | Lilly |
| 5897 | John Peipert | Northwestern University | Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid Arthritis | Pfizer |
| 5901 | Junhao Hu | Chinese Academy of Science | Vessel pericytes NO-sGC signaling in COVID-19 | Hannover Medical School |
| 5902 | Thrasyvoulos Tzellos | Norland University Hospital | Development and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativa | AbbVie |
| 5904 | Saskia Middeldorp | Amsterdam UMC | Hokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolism | Daiichi Sankyo |
| 5921 | Paul Schulz | University of Texas Health Science Center | Identification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medications | Lilly |
| 5924 | Iris Sommer | University Medical Center Groningen | Meta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies | AbbVie, GSK, Johnson & Johnson |
| 5925 | Min Hwan Kim | Yonsei University College of Medicine | Analysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical response | Pfizer |
| 5930 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy Boost in Women with HER-2 positive Breast Cancer | Roche |
| 5931 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial | Roche |
| 5933, 5208 | Ahmad Abuhelwa | University of South Australia | Predictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritis | Lilly, Roche, UCB |
| 5935 | Jian-Guo Zhou
| The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs) | Roche |
| 5940 | Aziz Mezlini | Massachusetts General Hospital | A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects | AbbVie, Boehringer Ingelheim, GSK, Johnson & Johnson, Lundbeck, Roche, Takeda, UCB |
| 5944 | Pietro Spitali | Leiden University Medical Center | Prediction of disease progression in Duchenne muscular dystrophy | CureDuchenne |
| 5945 | Neeraj Narula | McMaster University | Predictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITY | Takeda |
| 5948 | Georgia Salanti | University of Bern | Making real world predictions for clinical outcomes in Relapsing-Remitting Multiple Sclerosis | Biogen |
| 5950 | Shirley Wang | Brigham and Women's Hospital | Understanding effectiveness of new drugs in older adults shortly after market entry | Boehringer Ingelheim |
| 5951, 4543 | Mathilde Nijkeuter | UMC Utrecht | Individualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolism | Boehringer Ingelheim, Daiichi Sankyo |
| 5959 | John Dennis | University of Exeter Medical School | Stratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetes | Boehringer Ingelheim, Takeda |
| 5960 | Matt Linnik | Hannover Medical School | Covid-19 Pulmonary Gene Expression Analysis | Lilly |
| 5963 | Elyse Katz | USSAMMDA | A secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress Disorder | Lilly |
| 5968 | Mehul Patel | King's College Hospital NHS Foundation Trust | Methods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH) | Johnson & Johnson, Takeda |
| 5974 | Robert Schoevers | University of Groningen | Prescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD) | Lilly |
| 5981 | Mark Peterson | Vertex Pharmaceuticals | Identifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD) | CureDuchenne, Lilly |
| 5982 | Matthew Baker | Stanford University | Investigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment response | Roche |
| 5984 | David Baker | Queen Mary University of London | Exploring possibilities to improve the riskbenefit balance through anlaysis of the ocrelizumab phase II extension study | Roche |
| 5985, 5327 | Jose Antonio Pereira da Silva | Universidade de Coimbra, Portugal | Long-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysis | AbbVie, Pfizer, Roche, UCB |
| 5987 | Glen Hazlewood | University of Calgary | Disease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient data | AbbVie, Johnson & Johnson, Lilly, Pfizer, Roche, UCB |
| 5988 | Elad Sharon | National Cancer Institute | The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes | Roche |
| 5989 | Alexandre Betourne | Critical Path Institute | Sharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other Purposes | AbbVie |
| 5990 | Yan Luo | Kyoto University | Predicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis | AbbVie, Roche |
| 6003 | Andrea Quattrone | Magna Graecia University of Catanzaro | Evaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trials | AbbVie |
| 6004 | Lily Lim | University of Manitoba | Identifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change Treatment | Roche |
| 6006 | Nicholas White | Mahidol University | A Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19 | Pfizer |
| 6007 | Judith Goldstein | Johns Hopkins School of Medicine | National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD) | Roche |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors. | Roche |
| 6024 | Cosima Locher | University Hospital Zurich | Predictors of placebo response in opioid trials for patients with Chronic Primary Pain – An Individual-Patient Data (IPD) Meta-Analysis
| AbbVie |
| 6041 | Neeraj Narula | Hamilton Health Sciences | Histologic Predictors of Endoscopic Healing in Crohn's Disease | AbbVie |
| 6050 | Paul Cinciripini | UT MD Anderson Cancer Center | Safety and efficacy of smoking cessation treatments in smokers with and without depression | Pfizer |
| 6062 | Alex Meisel | University Hospital of Zurich | Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-Combinations | Roche |
| 6063 | Wiesje van der Flier | Amsterdam UMC, VUmc | Optimizing Trial design to Achieve Personalized prevention of Alzheimer’s disease | Boehringer Ingelheim, GSK, Johnson & Johnson, Lilly |
| 6064 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis | Johnson & Johnson, Takeda |
| 6066 | Vivek Sharma | University of Louisville | EVALUATING THE ASSOCIATION BETWEEN PROTEINURIA AND THROMBOSIS AND ITS PREDICTORS IN PATIENTS TREATED WITH BEVACIZUMAB | Boehringer Ingelheim, Lilly, Roche |
| 6068 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumaby | Roche |
| 6104 | Pratik Sinha | Washington University | Heterogeneous treatment effects in molecular phenotypes of sepsis | Lilly |
| 6115 | David McAllister | University of Glasgow | Real-world treatment effectiveness of novel anti-diabetic agents in people with type 2 diabetes: Maximising the applicability of clinical trials | AstraZeneca, Boehringer Ingelheim, GSK, Lilly, Takeda |
| 6118 | Roxana Mehran | Icahn School of Medicine at Mount Sinai | Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention: a systematic review and individual patient data network meta-analysis. | Boehringer Ingelheim, Daiichi Sankyo |
| 6464 | Michael Wiese | University of South Australia | Individualisation of gout flare prophylaxis when initiating urate-lowering therapy | Takeda |
| 6471 | Floris Bosch | University of Amsterdam Academic Medical Center | Risk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysis | Pfizer |
| 6472 | Soong June Bae | Yonsei University Health System | Impact of neutrophil to lymphocyte ratio on prognosis in patients with HER2-positive breast cancer regarding the HER2-targeted therapy | Roche |
| 6475 | Tobias Polak | Erasmus Medical Center | Combining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenib | Roche |
| 6477 | Tobias Polak | Erasmus Medical Center | Tositumomab: statistical modeling of expanded access programs and conventional trials | GSK |
| 6482 | Andreas Monsch | University of Basel | Analyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patients
| Takeda |
| 6483 | Bharati Kumar | University of Bath | Evaluation of available statistical methods performance under non-proportional hazards | AstraZeneca, Lilly |
| 6484 | Ari Rosenberg | University of Chicago | Developing predictive and prognostic Artificial Intelligent (AI) digital biomarkers for soft tissue sarcoma | Lilly |
| 6488 | Feng Sun | Peking University | An individual participant data meta-analysis to evaluate a new category of hypoglycemic drugs (SGLT-2Is) on type 2 diabetes mellitus patient sub-groups | Boehringer Ingelheim, Johnson & Johnson |
| 6489 | Line Uhrenholt | Aalborg University Hospital | Tapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthritis: a systematic review of randomised controlled trials | AbbVie |
| 6494 | Maria Alice Franzoi | Jules Bordet Institute | Implications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant setting | Lilly |
| 6495, 5485 | Günter Höglinger | Hanover Medical School | Application of improved statistical methodologies for clinical trials in Progressive Supranuclear Palsy | AbbVie |
| 6496 | Neeraj Narula | Hamilton Health Sciences | Endoscopic Disease Severity and Patient Reported Outcomes in Crohns Disease | AbbVie, Johnson & Johnson |
| 6498 | Timo Uphaus | University Medical Center Mainz | Identifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring system | Boehringer Ingelheim |
| 6499, 5323, 5289 | Ashley Hopkins | Flinders University | Predictors of therapeutic and adverse effects of medicines used in the treatment of breast cancer | AstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, Roche |
| 6515 | Leire Leache | Navarre Health Service | Cochrane Systematic Review Pharmacotherapy for hypertension induced left ventricular hypertrophy | Boehringer Ingelheim |
| 6520 | Thomas Schnitzer | Northwestern University | Development of model to predict pain response in clinical trials of chronic pain conditions | Pfizer |
| 6521 | Ethan Alt | University of North Carolina at Chapel Hill | Bayesian probability of success for multivariate generalized linear models | Biogen |
| 6532 | Odelia Cooper | Cedars-Sinai Medical Center | A study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumors | Lilly |
| 6534 | Diego Tosi | Institut du Cancer de Montpellier | Analysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatment | Lilly |
| 6541 | Dipak Kotecha | University of Birmingham | Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure | Boehringer Ingelheim |
| 6543 | Andreas Meid | Heidelberg University Hospital | Reproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics? | Roche |
| 6544 | Angela Wu | University of Oxford | Investigating the association between smoking cessation and mental health in people with and without psychiatric disorders | Pfizer |
| 6550 | James Brorson | The University of Chicago | Examination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrence | AstraZeneca |
| 6551 | Siddharth Singh | University of California San Diego | Predicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID Registry | AbbVie |
| 6593 | Matthieu Roustit | Grenoble Alpes University Hospital | Exploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomes | AstraZeneca |
| 6594 | Manju Subramanian | Boston Medical Center | The Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled Analysis | Roche |
| 6601 | Dan Turner | Shaare Zedek Medical Center | Adaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial data | AbbVie |
| 6629 | Jian-Guo Zhou | The Second Affiliated Hospital of Zunyi Medical University | Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) | AstraZeneca, Lilly, Roche |
| 6632 | Luca Valerio | University Medical Center of the Johannes Gutenberg-University Mainz | Healthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in venous thromboembolism (VTE) study | Daiichi Sankyo |
| 6633 | Luca Valerio | University Medical Center Mainz | Performance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer study | Daiichi Sankyo |
| 6641 | Anna Feeney | Massachusetts General Hospital | Antidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysis | Pfizer |
| 6642 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohns Disease | AbbVie, Johnson & Johnson, Takeda |
| 6686 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool | Takeda |
| 6710 | Gus Slotman | Inspira Health Network | Identifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced Mortality | Lilly |
| 6712 | Yeon-Mok Oh | Asan Medical Center | Development and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD) | GSK |
| 6716 | Nigam Shah | Stanford University | Applying machine learning tools to personalize dabigatran treatment decisions | Boehringer Ingelheim |
| 6732 | Yung-Chuan Huang | Fu Jen Catholic University Hospital | Decision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation Patients | Boehringer Ingelheim |
| 6734 | Andreas Suhrbier | QIMR Berghofer Medical Research institute | The K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humans | Hannover Medical School |
| 6739 | Rifaquat Rahman | Dana Farber Cancer Institute | Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma | Project Data Sphere, Roche |
| 6740 | Georgios Paliouras | National Centre for Scientific Research 'Demokritos' (NCSR-D) | in-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular Dystrophy | CureDuchenne |
| 6758 | Qian Chen | Hubei Cancer Hospital | Retrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapy | Roche |
| 6759, 5936 | Zhi Xiao | Xiangya Hospital, Central-South University | Roles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy | Roche |
| 6764 | Camila Olarte Parra | London School of Hygiene and Tropical Medicine | Hypothetical estimand in clinical trials: an application of causal inference and missing data methods | AstraZeneca |
| 6765 | Dan Hanley | Johns Hopkins University | Pandemic response COVID-19 Research Collaboration Platform | NYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans |
| 6836 | Alana Rojewski | Medical University of South Carolina | Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial | Pfizer |
| 6860 | Nicholas Lange | Columbia University | Belatacept in obese kidney transplant recipients | Bristol Myers Squibb |
| 6866 | Andy Lim | Monash University | Meta-analysis of early stroke recurrence rate in minor stroke | AstraZeneca |
| 6869 | Zhen Lin | Robot Bacon Corporation | Evaluating Clinical Trial Data Conventions for the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) | AstraZeneca, Ferox Therapeutics, GSK, Roche, Takeda |
| 6881, 5484 | Stefan Leucht | Technical University of Munich | Individual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia | Lilly, Pfizer |
| 7062 | Julien Edeline | Centre Eugene Marquis | PATIENT REPORTED OUTCOME (PRO) AS A PROGNOSTIC MARKER IN PATIENTS TREATED WITH TARGETED THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA (PRO²-HCC) | Bristol Myers Squibb |
| 7070 | Georgios Tsakonas | Karolinska Institutet | Anaplastic Lymphoma Kinase- Brain Prognostic Index (ALK-BPI) a novel prognostic score for brain metastasized ALK+ Non Small Cell Lung Cancer (NSCLC) | Roche |
| 7072 | James Signorovitch | Analysis Group | Development of natural history controls to contextualize clinical trial outcomes of boys with Duchenne muscular dystrophy treated with DS-5141B | CureDuchenne |
| 7074 | Gregory YH Lip | University of Liverpool | Impact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomes | Boehringer Ingelheim |
| 7076 | Elias Eriksson | University of Gothenburg | Post hoc patient-level analysis of the impact of amitriptyline, selective serotonin reuptake inhibitors, and placebo of individual items of the Hamilton Depression Rating Scale | GSK |
| 7077 | Neeraj Narula | Hamilton Health Sciences | Dominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohns Disease | AbbVie, Johnson & Johnson |
| 7078 | Alberto Martini
| San Raffaele University | Role of body mass index and Beta Blockers in metastatic urothelial carcinoma | Roche |
| 7101 | Jason Luke | University of Pittsburgh | Analysis of gene expression profiles in melanoma tumors exhibiting differential lactate dehydrogenase biomarker levels and correlation with immunotherapy response | Bristol Myers Squibb |
| 7104 | Jakob Näslund | University of Gothenburg | Item-level effects of adjuvant olanzapine and/or olanzapine monotherapy in treatment-resistant depression | Lilly |
| 7126 | Alessio Cortellini | Imperial College London | The predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer. | Roche |
| 7127 | Alexa Kimball | Beth Israel Deaconess Medical Center | Effects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis Suppurativa | AbbVie |
| 7136 | Shou-Ching TANG | University of Mississippi Medical Center (UMMC) Cancer Center and Research Inst. | Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancer | Roche |
| 7140 | Michael J. Sorich | Flinders University of South Australia | Early markers of clinical outcome to ipilimumab therapy for advanced melanoma | Bristol Myers Squibb |
| 7142 | Sara Tedeschi | Brigham and Women’s Hospital | Causal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with gout | Takeda |
| 7143 | Chaim Singal | experiMind | The effects of systemic anti-infective concomitant medications on progression of neurological diseases | Boehringer Ingelheim, GSK, Lilly, UCB |
| 7144 | Timothy Perk | AIQ Solutions | External validation of the AIQ predictive score of clinical benefit using Sodium Fluoride (NaF) position emission tomography/computed tomography (PET/CT) images in metastatic prostate cancer (mPC) | Pfizer |
| 7145 | Joan Busner | Signant Health | Psychometric evaluation of Positive and Negative Syndrome Scale (PANSS) in adolescent schizophrenia trials | Otsuka |
| 7147 | Carmela Tartaglia | University of Toronto | Exploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumes | AbbVie |
| 7156 | Angelina Tjokrowidjaja | University of Sydney | Concordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysis | AstraZeneca |
| 7158 | Neeraj Narula | Hamilton Health Sciences | Patient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative Colitis | Takeda |
| 7159, 6634 | James Signorovitch | Analysis Group, Inc. | Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD) | CureDuchenne |
| 7161 | Wesley Kerr | University of California, Los Angeles | Real time monitoring of individual response to antiseizure medication treatment during clinical trials | GSK, Johnson & Johnson, UCB |
| 7162 | Andrew Bottomley | European Organisation for Research and Treatment of Cancer (EORTC) | Cancer Clinical Trials Pooling of Quality Life Data (CATAPULT) initiative | Bristol Myers Squibb |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers | Project Data Sphere, Roche |
| 7164 | Jörg Ellinger | University Hospital Bonn | Evaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinoma | Roche |
| 7224 | Keiichi Fujiwara | Gynecologic Oncology Trial and Investigation Consortium (GOTIC) | Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technologyn | Boehringer Ingelheim, Lilly, Roche |
| 7225 | Neeraj Narula | Hamilton Health Sciences | Early vs. Delayed Response to Vedolizumab in Ulcerative Colitis | Takeda |
| 7227 | Catrin Tudur-Smith | University of Liverpool | Add-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysis | GSK, Johnson & Johnson, UCB |
| 7232 | Neil Oxtoby | University College London | Identification of heterogeneity in Alzheimer’s disease clinical trials using computational modelling | Takeda |
| 7233 | Gregory YH Lip | University of Liverpool | Evaluating the outcomes and characterisation of atrial fibrillation | Boehringer Ingelheim |
| 7241 | Frederick Reimherr | Psychiatric and Behavioral Solutions, LLC | Retrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by Brexpiprazole | Otsuka |
| 7243 | Emanual Maverakis | University of California Davis | Developing Models from Existing Atopic Dermatitis Outcome Data | GSK |
| 7245 | Manabu Takaki | Okayama University | Clinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan. | Otsuka |
| 7274 | Jun Chen | West China Hospital, Sichuan University | Efficacy comparison of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma — a network meta-analysis | GSK |
| 7277 | David Carter | MMS Holdings | International COVID-19 Data Alliance COVID-19 Workbench | Roche |
| 7283 | Franziska Michor | Dana Farber Cancer Institute | Large-scale public data reuse to model immunotherapy response and resistance | Bristol Myers Squibb |
| 7288 | Vipual Jairath | Alimentiv Inc. | Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled Trials | AbbVie, Johnson & Johnson, Takeda |
| 7289 | Gianluca Rigatelli | Rovigo General Hospital | Outcomes of Left Main Purcutaneous Coronary Intervention across age classes | Duke University |
| 7312 | Marianna Kruithof-de Julio | University of Bern | Machine learning for personalized drug response prediction for bladder and prostate cancer patients | Tempus Labs, Inc. |
| 7317 | Emanual Maverakis | University of California Davis | Developing Efficacy Assessment Tools from Existing Psoriasis Clinical Trial Outcome Data | Lilly |
| 7321 | Neeraj Narula | Hamilton Health Sciences | A Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative Colitis | Johnson & Johnson, Pfizer |
| 7322 | Zhengfei Zhu | Fudan University Shanghai Cancer Center | Clinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasis | Roche |
| 7323 | Toshifumi Kishimoto | Nara Medical University | Development of the optimal treatment of Nalmefene in patients with alcohol dependence | Otsuka |
| 7325 | Andreas Artemiou | Cardiff University | Predicting outcomes (death, improvement, survival) of COVID-19 patients on Standard of Care (SoC) | NYU Grossman School of Medicine, Roche, University Medical Center New Orleans |
| 7379 | Michele Romoli | Bufalini Hospital | Antithrombotics in patent formane ovale (PFO)-related stroke: a meta-analysis stratified for the risk of paradoxical embolism score (RoPE) | Boehringer Ingelheim |
| 7381 | Tomoya Hirota | University of California San Francisco | Early Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum Disorder | Johnson & Johnson, Otsuka |
| 7384 | Ulrich Mansmann | Ludwig-Maximilian’s University München | Application of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials | AstraZeneca, Roche, Takeda |
| 7387 | Neeraj Narula | Hamilton Health Sciences | Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s Disease | AbbVie, Johnson & Johnson, Takeda |
| 7388 | Byeongzu Ghang | Jeju National University Hospital | Reanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patients | Takeda |
| 7394, 6117, 5895 | Ashley Hopkins | Flinders University | Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers | Roche |
| 7395 | Xiaoling Shang | Shandong University | Survival analysis of advanced lung adenocarcinoma harboring epidermal growth factor receptor gene mutation receiving the combination treatment of atezolizumab, Bevacizumab,carboplatin and Paclitaxel | Roche |
| 7396 | Mary Ann Lukas | GSK | Modeling and Simulation of ambrisentan pharmacokinetics in young children | Duke University School of Medicine |
| 7399 | Yoichi Naito | National Cancer Center Hospital East | Correlation of doxorubicin dose and survival in patients with soft tissue sarcoma; Data from two studies (a larger phase III study and a smaller phase II study) will be combined and analyzed. | Lilly |
| 7400 | Aryelly Rodriguez | The University of Edinburgh | What are the re-identification risk scores of publicly available anonymised clinical trial datasets? | GSK, UCB |
| 7404 | Reena Khanna | Lawson Health Research Institute | A Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled Trials | Takeda |
| 7414 | Nobuyuki Horita | Yokohama City University Hospital | Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis. | Roche |
| 7427 | Joachim Tan | Monash University | Dose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis | AbbVie, Johnson & Johnson, Roche |
| 7435 | Noah Goldfarb | University of Minnesota | Decision tool for the use of adalimumab for hidradenitis suppurativa | AbbVie |
| 7445 | Catherine Thieblemont | Inserm | Evaluation of surrogate markers in marginal zone lymphoma | Roche |
| 7462 | Junjie Zhuo | Hainan University | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s Disease | AstraZeneca |
| 7492 | Yang Zhao | Nanjing Medical University | An Investigation on the Role of Blood Biomarkers as Predictors for Individualized Treatment Regimen Selection in Non-Small Cell Lung Cancer. | Roche |
| 7493 | Nina Hilkens | Radboudumc Nijmegen | Blood pressure variability and progression of white matter hyperintensities after ischemic strokes | Boehringer Ingelheim |
| 7495 | Thomas Antalffy | Smart Respiratory Products Ltd | Analysing Clinical Applicability of CompEx Endpoints | AstraZeneca |
| 7498 | Riccardo Polosa | Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) | A Machine Learning approach to improve smoking cessation trials | Pfizer |
| 7501 | Min-Gul Kim | Jeonbuk National University Hospital | COVID-19 clinical trial data utilization to develop external control datasets in COVID-19 therapeutics development | HCor Research Institute, Hospital Universitario Austral, Lilly, Montreal Heart Institute, Roche, University of Minnesota |
| 7503, 6635 | Leslie Padrnos | Mayo Clinic | Efficacy and safety of anticoagulants for the treatment of acute venous thromboembolism (VTE) in patients with hematologic malignancies a systematic review and individual patient level data meta-analysis | Boehringer Ingelheim, Daiichi Sankyo, Pfizer |
| 7518 | Lucio Manenti | University Hospital of Parma | Role of persistent and isolated reduced serum complement 3 (sC3) in lupus nephritis | Roche |
| 7520 | Malathi Ram | Johns Hopkins University | ACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysis | Bassett Medical Center, Sharp Healthcare, University of Kansas Medical Center, University of Minnesota |
| 7535 | Joshua Drago | Memorial Sloan Kettering Cancer Center | Statin use and clinical outcomes on ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer | Roche |
| 7539 | Amit Etkin | Alto Neuroscience, Inc. | Clinical and demographic predictors of antidepressant treatment in patients with major depressive disorder with agomelatine versus vortioxetine | Lundbeck |
| 7541 | Amit Etkin | Alto Neuroscience, Inc | Role of clinical, historical and demographic factors in the response to antidepressants versus placebo | Lilly, Takeda |
| 7542 | Neeraj Narula | Hamilton Health Sciences | Vedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect Comparisons | AbbVie, Takeda |
| 7543 | Margaret Salisbury | Vanderbilt University Medical Center | Defining the physiologic trajectory of presymptomatic through advanced pulmonary fibrosis | Boehringer Ingelheim, Roche |
| 7544 | Abhimanyu Mahajan | Rush University Medical Center | Sensory trick and benefit from botulinum toxin in cervical dystonia | AbbVie |
| 7549 | Vipul Jairath | Alimentiv Inc | Responsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative Colitis | AbbVie, Johnson & Johnson, Takeda |
| 7552 | Anna van Eijk | Liverpool School of Tropical Medicine | Impact of Malaria in Pregnancy on Infants | Pfizer |
| 7581 | Rustam Al-Shahi Salman | University of Edinburgh | Collaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH) | Daiichi Sankyo |
| 7583, 5932 | Youssef Zeidan | American University of Beirut Medical Center | Evaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer Patients | Roche |
| 7587 | Sudhir Sivakumaran | Critical Path Institute | Development of model-informed drug development tools for Alzheimer's Disease | Lilly |
| 7590 | Noémie Lang | University Hospitals of Geneva | FRILLY: a retrospective single center study on Fractionated Rituximab to avoid Lysis Syndrome in Aggressive B-Lymphoma | Project Data Sphere, Roche |
| 7591, 7392 | Neeraj Narula | Hamilton Health Sciences | Predictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s Disease | AbbVie, Johnson & Johnson, Pfizer, Takeda |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatment | Roche |
| 7597 | Junko Takeshita | University of Pennsylvania | Evaluating Racial and Ethnic Differences in the Quality-of-Life Impact of Atopic Dermatitis | Lilly, Pfizer, Regeneron |
| 7598 | Harry Southworth | Data Clarity Consulting Ltd | Exploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data mining | AstraZeneca, GSK |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Johnson & Johnson, Lundbeck, Takeda |
| 7601 | Guru Sonpavde | AdventHealth Cancer Institute | Mathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitors | Roche |
| 7606 | Amber Salter | University of Texas Southwestern Medical Center | Comorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple Sclerosis | Roche |
| 7609 | Joao Pedro Ferreira | Porto University | The impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baseline | GSK |
| 7620 | Emilie Sbidian | University Paris Est Creteil (UPEC) | Systemic pharmacological treatments for chronic plaque psoriasis A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB |
| 7621 | Adam Boxer | University of California San Francisco | Bayesian Disease Progression Modeling and Clinical Trial Design for Progressive Supranuclear Palsy - Richardson's Syndrome | AbbVie |
| 7654 | Shirley Yu | University of Sydney | Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritis | Sanofi |
| 7656 | Neeraj Narula | Hamilton Health Sciences | Impact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative Colitis | AbbVie, Johnson & Johnson, Pfizer, Takeda |
| 7658 | Arman Sabbaghi | Purdue University | Tripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 Treatments | Sanofi |
| 7660 | Shirley Yu | University of Sydney | Predictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysis | Sanofi |
| 7661 | Baocheng Chang | Tianjin Medical University | Effects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high risk | Sanofi |
| 7662 | Benoit You | Université Claude Bernard Lyon | Prognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA) | Sanofi |
| 7663, 7385 | Amit Etkin | Alto Neuroscience, Inc. | Cognitive predictors of antidepressant treatment outcome in patients with major depressive disorder | Lilly, Lundbeck, Takeda |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche,
Sanofi, Takeda |
| 7743 | Caroline Quach | CHU Sainte-Justine | Is there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-Analysis | Sanofi |
| 7744, 6055 | Florian Naudet | CHU Rennes | Inferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platforms | AbbVie, Boehringer Ingelheim, Lilly, Pfizer, Roche, Sanofi, Takeda, UCB |
| 7758 | Nahid Sultana | University of Sheffield | Indirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) | GSK |
| 7760 | John (Devin) Peipert | Northwestern University | Study of Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item as a Measure of Treatment Tolerability in Advanced Cancer Patients across Multiple Tumour Sites and Treatment Types | Lilly, Pfizer, Roche |
| 7772 | Neeraj Narula | Hamilton Health Sciences | Combined Histologic and Endoscopic Endpoints in Ulcerative Colitis | Takeda |
| 7776 | Stefan Leucht | Technical University of Munich | Antipsychotic drugs versus placebo in the treatment of antipsychotic naïve and/or first episode children or adolescents with psychosis: A systematic review and meta-analysis of double-blind randomized controlled | Lilly, Otsuka |
| 7777 | Paul Ayuk | Newcastle-upon-Tyne Hospitals NHS Trust | Using Dabigatran etexilate to prevent blood clots in women after childbirth | Boehringer Ingelheim |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | AstraZeneca |
| 7782 | Yang Li | Renmin University of China | A new covariate randomization method for multi-arm randomized controlled trials | GSK |
| 7785 | Christian Jonasson | NordicRWE | Using Norwegian real world data to emulate and reproduce results from oncology clinical trials | Roche |
| 7794 | Joan Carles | Vall D'Hebron Institute of Oncology | Co Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with Chemotherapy | Sanofi |
| 7797 | Jörg Ellinger | University Hospital Bonn | Evaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinoma | Pfizer, Project Data Sphere, Roche |
| 7801, 6864 | Yoshie Omachi | National Center of Neurology and Psychiatry | Elucidation of the predictive factors for active and placebo drug response on social functioning and quality of life (QOL) in psychiatric illnesses including developmental disorders | Johnson & Johnson, Lilly, Shionogi |
| 7804 | Qingyun Li | Genecast Biotechnology Co., Ltd | An exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancer | Roche |
| 7807 | Hayato Niiyama | Yokohama City University | A Post-hoc Analysis using Secondary Data of Clinical Trial from M14-033 Study to Evaluate Average Treatment Effect and Heterogeneous Treatment Effect of Adalimumab in Maintenance Phase for Patients with Ulcerative Colitis | AbbVie |
| 7809 | David James Pinato | Imperial College, London | The predictive role of concomitant antibiotics in patients treated with immunotherapy or oral treatment for unresectable hepatocellular carcinoma (HCC) | Roche |
| 7810 | Diego Chowell | Icahn School of Medicine at Mount Sinai | Machine learning model to predict cancer immunotherapy response | Roche |
| 7817 | Neeraj Narula | Hamilton Health Sciences | Predictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic Esophagitis | GSK |
| 7818 | Werner Weitschies | University of Greifswald | Development and improvement of an in vitro tool, which simulates the physiological characteristics of the ascending colon | Sanofi |
| 7819 | Jeanine Roeters van Lennep | Erasmus University Medical Center | Efficacy & Safety of Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors: a Systematic Review and Meta-analysis of Real-World Data | Sanofi |
| 7822 | Linbin Lu | the 900th Hospital of PLA | Trajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatment | Roche |
| 7823 | Marc Carrier | University of Ottawa | Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review | GSK, Sanofi |
| 7824 | Feng Sun | Peking University | An individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patients | Daiichi Sankyo, Roche |
| 7826 | Carl Turesson | Lund University | Efficacy and safety of tumor necrosis factor inhibitors (TNFi) in seronegative rheumatoid arthritis patients who are inadequate responders to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). A systematic literature review with meta-analysis. | AbbVie, Johnson & Johnson, Lilly, UCB |
| 7828 | Ramiro Sofia | Leiden University Medical Center | SPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB |
| 7830 | Yi-Wen Tsai | National Yang Ming Chiao Tung University | Cost effectiveness analysis of atezolizumab plus chemotherapy for untreated extensive stage small cell lung cancer in Asia | Roche |
| 7835 | Hiroyuki Kusuhara | University of Tokyo | Assessment of the drug-drug interactions risks of drugs based on the clinical data of the plasma biomarkers | AbbVie |
| 7840 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Clinical Effect of Chemotherapy-Immunotherapy Combination in the First-Line Treatment of Older Patients with Non-Small Cell Lung Cancer | Roche |
| 7842 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Pooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer | Roche |
| 7844 | Linong Ji | Peking University People's Hospital | Risk stratification and responder identification for glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Type 2 Diabetes Mellitus (T2DM): a machine learning facilitated post-hoc analysis of clinical trials | BioLINCC, GSK, Johnson & Johnson |
| 7845 | Craig Nelson | University of California San Francisco | Change in cognition during antidepressant treatment of late life depression | Lilly, Lundbeck |
| 7848 | Jennifer Lund | University of North Carolina at Chapel Hill | Improving Colon Cancer Therapy Decisions by Extending Trial Representation | Sanofi |
| 7849 | Linda Marchioro | Paul-Ehrlich-Institut | Determinants of study design for vaccines against opportunistic bacterial infections a proof-of-concept for data-driven, individual patient data (IPD) analyses. | Sanofi |
| 7850 | Vipul Jairath | University of Western Ontario | Impact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel Disease | AbbVie, Johnson & Johnson, Pfizer, Takeda, UCB |
| 7854 | Vipul Jairath | University of Western Ontario | Efficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trials | AbbVie, Johnson & Johnson, Pfizer, Takeda |
| 7856 | Evandro de Azambuja | Institut Jules Bordet | Metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survival | Roche |
| 7857 | Rentao Yu | Chongqing Medical University | Cutaneous adverse effects of immunotherapy medications in the treatment of cancers and their associations with overall survival | Daiichi Sankyo, Roche |
| 7858 | Jie Zha | Xiamen University | Retrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patients | Roche |
| 7860 | Kemi Williams | 54gene | Descriptive analysis of UNITY Global study data in Nigeria | Certara |
| 7868 | Anne-Marie Dingemans | Erasmus MC University Medical Center | Predictive clinical characteristics for weight gain in patients treated with alectinib | Roche |
| 7873 | Xue Yang | Beijing Cancer Hospital | Crizotinib followed by alectinib vs alectinib alone: analysis of treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) -rearrangement | Roche |
| 7874 | Chiara Alessandra Cella | Istituto Europeo di Oncologia | Addressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials. | Pfizer |
| 7875 | Marco Valgimigli | Cardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI) | P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative) | Sanofi |
| 7882 | José González-Gomariz | Fundacion para la Investigacion Medica Aplicada (FIMA) | Study of the expression of several cytokines related with the survival of advanced melanoma patients | Bristol Myers Squibb |
| 8052 | Wataru Fukuokaya | The Jikei University School of Medicine | Association of serum magnesium levels with effectiveness of atezolizumab in advanced urothelial carcinoma | Roche |
| 8056 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of clinical trial individual-participant data | Roche |
| 8175 | Guoxing Wan | Hubei University of Medicine | Efficacy and safety of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Roche |
| 8180 | Sheng Luo | Duke University | Clinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancer | Daiichi Sankyo, Lilly, Pfizer, Roche |
| 8236 | Gao-Jun Teng | Zhongda Hospital, Southeast University | The role of prior transarterial chemoembolization in atezolizumab plus bevacizumab in hepatocellular carcinoma | Roche |
| 8244 | Frank Doyle | Royal College of Surgeons Ireland | Do psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomes | GSK, Lilly, Pfizer, Takeda |
| 8263 | George Ntaios | University of Thesaly | Risk of myocardial infarction in patients with paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient data meta-analysis of the ENGAGE-AF and RE-LY trials | Boehringer Ingelheim, Daiichi Sankyo |
| 8266 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | The prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitis | Takeda |
| 8287 | Damian J. Ralser | University Hospital Bonn | Evaluation of the easy-to-implement modified Glasgow prognostic score (mGPS) in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer in the KATE2 clinical trial | Roche |
| 8294 | Neeraj Narula | Hamilton Health Sciences | Extended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with Tofacitinib | Pfizer |
| 8316 | Vipul Jairath | Alimentiv | Correlation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn’s Disease | AbbVie, Johnson & Johnson, Pfizer, Takeda |
| 8324 | Jeroen Dekervel | Universitaire Ziekenhuizen Leuven | Response Evaluation Criteria in Solid Tumors (RECIST) vs modified RECIST response durability in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Roche |
| 8325 | Xiaodan Tang | Northwestern University | Does scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response Theory | AbbVie |
| 8327 | Eva Hoster | Ludwig-Maximilian University Munich | Constructing estimands for overall survival within causal frame work for dynamic treatment schemes in oncology: Simulation and a clinical trial example | Roche |
| 8342, 7444 | Gus Slotman | Inspira Health Network | IDENTIFYING TOCILIZUMAB-RESPONSIVE COVID-19 PATIENTS FROM COVACTA, EMPACTA, AND REMDACTA RANDOMIZED CLINICAL TRIAL PRE-RANDOMIZATION DATA | Roche |
| 8344 | Xiaoling Shang | Shandong University | A clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide | Roche |
| 8347 | Hong Jae Chon | CHA Bundang Medical Center | Thyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab | Roche |
| 8349 | Nqoba Tsabedze | University of Witwatersrand | The efficacy of beta-blockers on morbidity and mortality endpoints in black hypertensive patients: A meta-analysis | GSK |
| 8377 | Neeraj Narula | Hamilton Health Services | Estimating Differences in the Comparison of Outcomes in Clinical Trials for Ulcerative Colitis Patients using Patient-Level Data and Aggregated Data Network Meta-Analysis | AbbVie, Johnson & Johnson, Pfizer, Takeda |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Johnson & Johnson, Sanofi, Takeda |
| 8435 | Hui Zheng | Chengdu University of Traditional Chinese Medicine | Predictors of galcanezumab in the preventive treatment of migraine | Lilly |
| 8436 | David Schade | NM Non profit Society to Prevent Symptomatic Heart Disease | Development of an Atherosclerosis Reversal Calculator | AstraZeneca |
| 8438 | Sheng Luo | Duke University | Development of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over time | AbbVie |
| 8440 | David Seiffge | Insel Gruppe AG | Andexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC | AstraZeneca |
| 8445 | Kelley Kidwell | University of Michigan | Use of external control with longitudinal data for drug evaluation in Duchenne muscular dystrophy a Bayesian small sample, sequential, multiple assignment randomized trial design (snSMART) | CureDuchenne, Lilly |
| 8446, 7479, 7075 | Elias Eriksson | University of Gothenburg | Efficacy of serotonin reuptake inhibitors in children and adolescents | AbbVie, GSK, Lilly, Lundbeck, Pfizer |
| 8450 | Dennis McGonagle | University of Leeds | The effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patients | Lilly |
| 8542 | João Sérgio Neves | Faculty of Medicine of University of Porto | Albiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use | GSK |
| 8557 | Fan Ge | Guangzhou Medical University | Organ-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancer | Lilly, Roche |
| 8558 | Pablo Guisado Vasco | Hospital Universitario Quironsalud Madrid | Investigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patients | Roche |
| 8559 | Dag Aarsland | King’s College London | Predicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine Antidepressants | Lundbeck |
| 8563 | Kenta Yoshida | Genentech, Inc. | Tumor Growth Inhibition-Overall Survival (TGI-OS) model development and validation for hormone receptor positive (HR+)human epidermal growth factor receptor 2 negative (HER2-) breast cancer | Pfizer |
| 8564 | SANGWOO KIM | Yonsei University Health System | Development of Immune Phenotype-specific Immune Checkpoint Inhibitor Response (anti-programmed death ligand-1) Prediction Algorithm | Bristol Myers Squibb |
| 8569 | Gus Slotman | Inspira Health Network | USING PRE-RANDOMIZATION DATA TO IDENTIFY PATIENTS WITH COVID-19 AMONG WHOM FLUVOXAMINE OR IVERMECTIN IMPROVED OUTCOMES | Platform Life Sciences |
| 8585 | Daniel Schachter | Unigranrio | Efficacy of Calcitonin gene-related peptide (CGRP) monoclonal antibodies for medication overuse headache in chronic migraine patients A systematic review and meta-analysis | Lilly, Lundbeck |
| 8588 | Wenlong Zhong | Sun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSU) | The influence of antibiotics on survival outcomes for bladder cancer patients being treated with immune checkpoint inhibitor therapy | Roche |
| 8593 | Hyon Choi | Massachusetts General Hospital | Serum urate reduction, gout flares, and risk of major cardiovascular events during urate-lowering therapy initiation target trial emulation and self-controlled case series analysis | Takeda |
| 8603 | Wencai Jiang | Chengdu Second People's Hospital | Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease | GSK |
| 8606 | Daria Igudesman | AdventHealth Translational Research Institute | Evaluating the association of eating window duration and timing of calorie distribution with glycemic parameters and body weight | Jaeb Center for Health Research Foundation, Inc. |
| 8609 | Fredrik Schjesvold | Oslo University Hospital | Personalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling. | Sanofi |
| 8699 | Niklas Klümper | University Hospital Bonn | Evaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers | Roche |
| 8700 | Leo Buckley | Brigham and Women's Hospital | Colchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatment | Montreal Heart Institute |
| 8720 | George Ntaios | University of Thessaly | Association between statin treatment and cardiovascular outcomes in patients with atrial fibrillation | Boehringer Ingelheim, Daiichi Sankyo |
| 8751 | Diederik Dippel | Erasmus MC University Medical Center | Prediction of the treatment benefit of intravenous alteplase treatment for acute ischemic stroke | Boehringer Ingelheim |
| 8753 | Issa Dahabreh | Harvard T.H. Chan School of Public Health | Dabigatran versus Warfarin in Patients with Atrial Fibrillation Extending inference from the RE-LY trial to real world target population | Boehringer Ingelheim |
| 8756 | Eyal Dassau | Eli Lilly and Company | Assessment of insulin utilization and insulin delivery metrics in people with type 1 diabetes mellitus using blood glucose excursions, combined with nutrition and exercise information from the T1-DEXI dataset | Jaeb Center for Health Research Foundation, Inc. |
| 8757 | Sandra Tessa Hattenhauer | University Hospital Bonn | Baseline immune signature score as predictor for response to atezolizumabbevacizumab in hepatocellular carcinoma | Roche |
| 8758 | Michael Szarek | CPC Clinical Research | Comparison of RGX-202-01 with ramucirumab or aflibercept in the treatment of patients with recurrent colorectal cancer harboring a RAS mutation | Lilly, Sanofi |
| 8775 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Predictors for therapeutic outcomes in patients of ulcerative colitis receiving Janus kinase inhibitors | Galapagos, Pfizer |
| 8806 | Timothy Gaulton | Massachusetts General Hospital | Understanding the impact of body mass index on the effectiveness of baricitinib as a treatment for individuals hospitalized with COVID-19 | Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health) |
| 8809 | Jing Yu | Sichuan University | Constructing a predictive model for lung cancer immunotherapy | Tempus Labs, Inc. |
| 8893 | Eleonora Manzoni | University of Padova | Detection and prediction of physical activity in type 1 diabetic subjects. | Jaeb Center for Health Research Foundation, Inc. |
